Sumitomo Pharma Am Drug Patent Portfolio

Sumitomo Pharma Am owns 6 orange book drugs protected by 66 US patents with Gemtesa having the least patent protection, holding only 5 patents. And Kynmobi with maximum patent protection, holding 19 patents. Given below is the list of Sumitomo Pharma Am's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12357636 04 May, 2042
Active
US12102638 Use of vibegron to treat overactive bladder 22 Mar, 2040
Active
US11793812 Methods of treating endometriosis 03 May, 2038
Active
US11033551 Methods of treating uterine fibroids 29 Sep, 2037
Active
US11957684 Treatment of heavy menstrual bleeding associated with uterine fibroids 29 Sep, 2037
Active
US10449191 Treatment of prostate cancer 29 Sep, 2037
Active
US10786501 Treatment of prostate cancer 29 Sep, 2037
Active
US11583526 Treatment of prostate cancer 29 Sep, 2037
Active
US12097198 Treatment of prostate cancer 29 Sep, 2037
Active
US12144809 Treatment of prostate cancer 29 Sep, 2037
Active
US12336990 Treatment of prostate cancer 29 Sep, 2037
Active
US10744277 Aerosol delivery device and method of operating the aerosol delivery device 07 Dec, 2036
Active
US10688518 Method of manufacturing a vibratable head for an aerosol generator and vibratable head for an aerosol generator 12 Nov, 2036
Active
US10449146 Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa 19 Apr, 2036
Active
US10959943 Methods of treating Parkinson's disease by administration of apomorphine to an oral mucosa 19 Apr, 2036
Active
US10350170 Solid preparation 25 Feb, 2036
Active
US10376661 Opening element for opening an ampoule in an aerosol generation device and aerosol generation device comprising the opening element 14 Sep, 2035
Active
US12180219 Process for preparing beta 3 agonists and intermediates 12 Mar, 2034
Active
US11795178 Compositions of thienopyrimidine derivatives 27 Sep, 2033
Active
US12325714 Compositions of thienopyrimidine derivatives 27 Sep, 2033
Active
US9604018 Aerosol therapy device 16 May, 2033
Active
US9168556 Membrane nebulizer and method for welding a membrane to a carrier during the production of a membrane nebulizer 01 Sep, 2032
Active
US9750747 Treatments involving eslicarbazepine acetate or eslicarbazepine 24 Aug, 2032
Active
US11419769 Sublingual films 16 Dec, 2031
Active
US8414922 Sublingual films 16 Dec, 2031
Active
US8846074 Sublingual films 16 Dec, 2031
Active
US8247415 Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists 01 Dec, 2030
Active
US9789270 Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized 30 Oct, 2030
Active
US10420763 Sublingual apomorphine 11 Jun, 2030
Active
US9044475 Sublingual apomorphine 11 Jun, 2030
Active
US9283219 Sublingual films 11 Jun, 2030
Active
US9326981 Sublingual apomorphine 11 Jun, 2030
Active
US9669019 Sublingual apomorphine 11 Jun, 2030
Active
US9669021 Sublingual apomorphine 11 Jun, 2030
Active
US8372431 Pharmaceutical composition comprising licarbazepine acetate 17 Apr, 2030
Active
US10821074 Sublingual and buccal film compositions 07 Aug, 2029
Active
US8653260 Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists 02 Apr, 2029
Active
US10940110 Method and system for the treatment of chronic COPD with nebulized anticholinergic administrations 26 Feb, 2029
Active
US9265900 Disposable ampoule for an aerosol generating device 07 Dec, 2028
Active
US10912781 Pharmaceutical composition comprising licarbazepine acetate 23 Oct, 2028
Active
US9566244 Pharmaceutical composition comprising licarbazepine acetate 23 Oct, 2028
Active
US9763954 Therapeutical uses of eslicarbazepine 13 Sep, 2028
Active
US11278683 Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized 16 Aug, 2026
Active
US9206135 Asymmetric catalytic reduction of oxcarbazepine 21 Apr, 2026
Active
US9643929 Asymmetric catalytic reduction of oxcarbazepine 21 Apr, 2026
Active
US7300935 Thienopyrimidine compounds and use thereof 28 Jan, 2026
Active
US8058280 Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof 28 Jan, 2026
Active
US7931212 Fluid droplet production apparatus and method 25 Nov, 2025
Active
US10675287 Methods of treatment of partial onset seizures using eslicarbazepine acetate 06 May, 2025 Expired
US10695354 Methods of treatment of partial onset seizures using eslicarbazepine acetate 06 May, 2025 Expired
US10702536 Methods of treatment of partial onset seizures using eslicarbazepine acetate 06 May, 2025 Expired
US11364247 Methods of treatment of partial onset seizures using eslicarbazepine acetate 06 May, 2025 Expired
US7458372 Inhalation therapy device 18 Nov, 2024 Expired
US8603514 Uniform films for rapid dissolve dosage form incorporating taste-masking compositions 03 Apr, 2024 Expired
US8765167 Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions 20 Feb, 2024 Expired
US9346822 Thienopyrimidine compounds and use thereof 17 Feb, 2024 Expired
US8735401 Thienopyrimidine compounds and use thereof 04 Feb, 2024 Expired
US8511581 Fluid droplet production apparatus and method 08 Nov, 2023 Expired
US8663687 Film compositions for delivery of actives 02 Feb, 2023 Expired
US7316067 Forming a perforate membrane by laser drilling and a subsequent electro-polishing step 06 Sep, 2022 Expired
US10888499 Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom 14 Feb, 2022 Expired
US11077068 Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions 14 Feb, 2022 Expired
US9855221 Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions 14 Feb, 2022 Expired
US9931305 Uniform films for rapid dissolve dosage form incorporating taste-masking compositions 14 Feb, 2022 Expired
US5753646 Substituted dihydrodibenzo/b,f/azepines, method of their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them 27 Jun, 2021 Expired
US6962151 Inhalation nebulizer 27 Oct, 2020 Expired


Given below is the list of recent legal activities going on the following drug patents of Sumitomo Pharma Am.

Activity Date Patent Number
Patent litigations
Recordation of Patent eCertificate of Correction 09 Jul, 2024 US10786501
Email Notification 09 Jul, 2024 US10786501
Mail Patent eCofC Notification 09 Jul, 2024 US10786501
Patent eCofC Notification 09 Jul, 2024 US10786501
Mail Certificate of Correction Memo 02 Jul, 2024 US10449191
Mail Certificate of Correction Memo 02 Jul, 2024 US11583526
Post Issue Communication - Certificate of Correction 01 Jul, 2024 US10449191
Post Issue Communication - Certificate of Correction 01 Jul, 2024 US11583526
Certificate of Correction Memo 30 Jun, 2024 US10449191
Certificate of Correction Memo 30 Jun, 2024 US11583526
Post Issue Communication - Certificate of Correction 17 Jun, 2024 US10786501
Mail Certificate of Correction Memo 12 Jun, 2024 US10786501
Certificate of Correction Memo 07 Jun, 2024 US10786501
Email Notification 17 Apr, 2024 US11957684
Patent Issue Date Used in PTA Calculation 16 Apr, 2024 US11957684


Sumitomo Pharma Am's Drug Patent Litigations

Sumitomo Pharma Am's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 28, 2014, against patent number US8765167. The petitioner BioDelivery Sciences International, Inc., challenged the validity of this patent, with MonoSol Rx, LLC. as the respondent. Click below to track the latest information on how companies are challenging Sumitomo Pharma Am's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8603514 June, 2017 Institution Denied
(20 Oct, 2017)
MonoSol Rx, LLC et al. Par Pharmaceutical, Inc. et al.
US8603514 June, 2017 Terminated-Denied
(20 Oct, 2017)
MonoSol Rx, LLC Par Pharmaceutical, Inc.
US8603514 June, 2017 Institution Denied
(20 Oct, 2017)
MonoSol Rx, LLC et al. Dr. Reddy’s Laboratories, Inc. et al.
US8603514 June, 2017 Terminated-Denied
(20 Oct, 2017)
MonoSol Rx, LLC Dr. Reddy’s Laboratories, Inc.
US8603514 November, 2016 Terminated-Settled
(06 Oct, 2017)
MonoSol Rx, LLC et al. Mylan Technologies, Inc. et al.
US8603514 May, 2016 Institution Denied
(05 Dec, 2016)
MonoSol Rx, LLC et al. Dr. Reddy's Laboratories, Inc. et al.
US8603514 May, 2016 Terminated-Denied
(05 Dec, 2016)
MonoSol Rx, LLC Dr. Reddy's Laboratories, Inc.
US8603514 December, 2015 Institution Denied
(23 May, 2016)
MONOSOL RX LLC et al. Teva Pharmaceuticals USA Inc
US8603514 December, 2015 Terminated-Denied
(23 May, 2016)
MONOSOL RX LLC Teva Pharmaceuticals USA Inc
US8765167 October, 2014 Final Written Decision
(24 Mar, 2016)
MonoSol Rx, LLC. et al. BioDelivery Sciences International, Inc.
US8765167 October, 2014 FWD Entered
(24 Mar, 2016)
MonoSol Rx, LLC. BioDelivery Sciences International, Inc.
US8765167 October, 2014 Terminated-Settled
(24 Mar, 2016)
MonoSol Rx, LLC. et al. BioDelivery Sciences International, Inc.
US8765167 October, 2014 Institution Denied
(20 May, 2015)
MonoSol Rx, LLC. et al. BioDelivery Sciences International, Inc.
US8765167 October, 2014 Terminated-Denied
(20 May, 2015)
MonoSol Rx, LLC. BioDelivery Sciences International, Inc.


Sumitomo Pharma Am Drug Patents' Oppositions Filed in EPO

Sumitomo Pharma Am drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 11, 2012, by Lts Lohmann Therapie-Systeme Ag. This opposition was filed on patent number EP02801042A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP17823018A Dec, 2022 SANDOZ AG Granted and Under Opposition
EP14815314A Feb, 2021 Vectura Limited Opposition rejected
EP15175258A May, 2019 D Young & Co LLP Granted and Under Opposition
EP08842368A Jun, 2017 Alfred E. Tiefenbacher (GmbH & Co. KG) Opposition rejected
EP08705172A Jun, 2017 Alfred E. Tiefenbacher (GmbH & Co. KG) Revoked
EP08705172A Jun, 2017 Ter Meer Steinmeister & Partner Patentanwälte mbB Revoked
EP10786915A May, 2016 LTS LOHMANN Therapie-Systeme AG Granted and Under Opposition
EP10786915A May, 2016 Generics (U.K.) Limited Granted and Under Opposition
EP11157819A Jun, 2014 Ahrens, Gabriele Patent maintained as amended
EP02782151A Jun, 2013 Acino Pharma AG Revoked
EP02782151A Jun, 2013 Germann, Sandra Revoked
EP02801042A Sep, 2012 Ahrens, Gabriele Patent maintained as amended
EP02801042A Sep, 2012 LTS LOHMANN Therapie-Systeme AG Patent maintained as amended


Sumitomo Pharma Am's Family Patents

Sumitomo Pharma Am drugs have patent protection in a total of 52 countries. It's US patent count contributes only to 30.9% of its total global patent coverage. 9 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Sumitomo Pharma Am Drug List

Given below is the complete list of Sumitomo Pharma Am's drugs and the patents protecting them.


1. Aptiom

Aptiom is protected by 12 patents, out of which 5 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9750747 Treatments involving eslicarbazepine acetate or eslicarbazepine 24 Aug, 2032
(6 years from now)
Active
US8372431 Pharmaceutical composition comprising licarbazepine acetate 17 Apr, 2030
(4 years from now)
Active
US10912781 Pharmaceutical composition comprising licarbazepine acetate 23 Oct, 2028
(3 years from now)
Active
US9566244 Pharmaceutical composition comprising licarbazepine acetate 23 Oct, 2028
(3 years from now)
Active
US9763954 Therapeutical uses of eslicarbazepine 13 Sep, 2028
(2 years from now)
Active
US9206135 Asymmetric catalytic reduction of oxcarbazepine 21 Apr, 2026
(6 months from now)
Active
US9643929 Asymmetric catalytic reduction of oxcarbazepine 21 Apr, 2026
(6 months from now)
Active
US10675287 Methods of treatment of partial onset seizures using eslicarbazepine acetate 06 May, 2025
(4 months ago)
Expired
US10695354 Methods of treatment of partial onset seizures using eslicarbazepine acetate 06 May, 2025
(4 months ago)
Expired
US10702536 Methods of treatment of partial onset seizures using eslicarbazepine acetate 06 May, 2025
(4 months ago)
Expired
US11364247 Methods of treatment of partial onset seizures using eslicarbazepine acetate 06 May, 2025
(4 months ago)
Expired
US5753646 Substituted dihydrodibenzo/b,f/azepines, method of their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them 27 Jun, 2021
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aptiom's drug page


2. Gemtesa

Gemtesa is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12357636 04 May, 2042
(16 years from now)
Active
US12102638 Use of vibegron to treat overactive bladder 22 Mar, 2040
(14 years from now)
Active
US12180219 Process for preparing beta 3 agonists and intermediates 12 Mar, 2034
(8 years from now)
Active
US8247415 Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists 01 Dec, 2030
(5 years from now)
Active
US8653260 Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists 02 Apr, 2029
(3 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Gemtesa's drug page


3. Kynmobi

Kynmobi is protected by 19 patents, out of which 7 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10449146 Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa 19 Apr, 2036
(10 years from now)
Active
US10959943 Methods of treating Parkinson's disease by administration of apomorphine to an oral mucosa 19 Apr, 2036
(10 years from now)
Active
US11419769 Sublingual films 16 Dec, 2031
(6 years from now)
Active
US8414922 Sublingual films 16 Dec, 2031
(6 years from now)
Active
US8846074 Sublingual films 16 Dec, 2031
(6 years from now)
Active
US10420763 Sublingual apomorphine 11 Jun, 2030
(4 years from now)
Active
US9044475 Sublingual apomorphine 11 Jun, 2030
(4 years from now)
Active
US9283219 Sublingual films 11 Jun, 2030
(4 years from now)
Active
US9326981 Sublingual apomorphine 11 Jun, 2030
(4 years from now)
Active
US9669019 Sublingual apomorphine 11 Jun, 2030
(4 years from now)
Active
US9669021 Sublingual apomorphine 11 Jun, 2030
(4 years from now)
Active
US10821074 Sublingual and buccal film compositions 07 Aug, 2029
(3 years from now)
Active
US8603514 Uniform films for rapid dissolve dosage form incorporating taste-masking compositions 03 Apr, 2024
(1 year, 6 months ago)
Expired
US8765167 Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions 20 Feb, 2024
(1 year, 7 months ago)
Expired
US8663687 Film compositions for delivery of actives 02 Feb, 2023
(2 years ago)
Expired
US10888499 Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom 14 Feb, 2022
(3 years ago)
Expired
US11077068 Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions 14 Feb, 2022
(3 years ago)
Expired
US9855221 Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions 14 Feb, 2022
(3 years ago)
Expired
US9931305 Uniform films for rapid dissolve dosage form incorporating taste-masking compositions 14 Feb, 2022
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kynmobi's drug page


4. Lonhala Magnair Kit

Lonhala Magnair Kit is protected by 14 patents, out of which 4 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10744277 Aerosol delivery device and method of operating the aerosol delivery device 07 Dec, 2036
(11 years from now)
Active
US10688518 Method of manufacturing a vibratable head for an aerosol generator and vibratable head for an aerosol generator 12 Nov, 2036
(11 years from now)
Active
US10376661 Opening element for opening an ampoule in an aerosol generation device and aerosol generation device comprising the opening element 14 Sep, 2035
(9 years from now)
Active
US9604018 Aerosol therapy device 16 May, 2033
(7 years from now)
Active
US9168556 Membrane nebulizer and method for welding a membrane to a carrier during the production of a membrane nebulizer 01 Sep, 2032
(6 years from now)
Active
US9789270 Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized 30 Oct, 2030
(5 years from now)
Active
US10940110 Method and system for the treatment of chronic COPD with nebulized anticholinergic administrations 26 Feb, 2029
(3 years from now)
Active
US9265900 Disposable ampoule for an aerosol generating device 07 Dec, 2028
(3 years from now)
Active
US11278683 Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized 16 Aug, 2026
(10 months from now)
Active
US7931212 Fluid droplet production apparatus and method 25 Nov, 2025
(a month from now)
Active
US7458372 Inhalation therapy device 18 Nov, 2024
(10 months ago)
Expired
US8511581 Fluid droplet production apparatus and method 08 Nov, 2023
(1 year, 10 months ago)
Expired
US7316067 Forming a perforate membrane by laser drilling and a subsequent electro-polishing step 06 Sep, 2022
(3 years ago)
Expired
US6962151 Inhalation nebulizer 27 Oct, 2020
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lonhala Magnair Kit's drug page


5. Myfembree

Myfembree is protected by 8 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11793812 Methods of treating endometriosis 03 May, 2038
(12 years from now)
Active
US11033551 Methods of treating uterine fibroids 29 Sep, 2037
(11 years from now)
Active
US11957684 Treatment of heavy menstrual bleeding associated with uterine fibroids 29 Sep, 2037
(11 years from now)
Active
US11795178 Compositions of thienopyrimidine derivatives 27 Sep, 2033
(7 years from now)
Active
US12325714 Compositions of thienopyrimidine derivatives 27 Sep, 2033
(7 years from now)
Active
US7300935 Thienopyrimidine compounds and use thereof 28 Jan, 2026
(3 months from now)
Active
US8058280 Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof 28 Jan, 2026
(3 months from now)
Active
US9346822 Thienopyrimidine compounds and use thereof 17 Feb, 2024
(1 year, 7 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Myfembree's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Orgovyx

Orgovyx is protected by 12 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10449191 Treatment of prostate cancer 29 Sep, 2037
(11 years from now)
Active
US10786501 Treatment of prostate cancer 29 Sep, 2037
(11 years from now)
Active
US11583526 Treatment of prostate cancer 29 Sep, 2037
(11 years from now)
Active
US12097198 Treatment of prostate cancer 29 Sep, 2037
(11 years from now)
Active
US12144809 Treatment of prostate cancer 29 Sep, 2037
(11 years from now)
Active
US12336990 Treatment of prostate cancer 29 Sep, 2037
(11 years from now)
Active
US10350170 Solid preparation 25 Feb, 2036
(10 years from now)
Active
US11795178 Compositions of thienopyrimidine derivatives 27 Sep, 2033
(7 years from now)
Active
US12325714 Compositions of thienopyrimidine derivatives 27 Sep, 2033
(7 years from now)
Active
US7300935 Thienopyrimidine compounds and use thereof 28 Jan, 2026
(3 months from now)
Active
US8058280 Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof 28 Jan, 2026
(3 months from now)
Active
US8735401 Thienopyrimidine compounds and use thereof 04 Feb, 2024
(1 year, 7 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Orgovyx's drug page